Main Menu

The National Institute of Allergy and Infectious Diseases has invented three chlamydial vaccine technologies, which have shown promising preclinical efficacy. Chlamydia trachomatis infection is the most common sexually transmitted bacterial infection. If left untreated, chlamydia infection can lead to pelvic inflammatory disease and infertility. Chlamydia is also the leading cause of preventable blindness in the world. Despite increased surveillance, prevalence continues to increase, and the need to develop an effective chlamydial vaccine remains.

Technologies:

A hybridoma cell line producing a monoclonal rat antibody specific to mouse CD25 (IL-2 receptor, alpha chain) (clone 3C7) as described in J Immunol. 1984 Oct;133(4):1970-5 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal rat antibody specific to mouse CD25 (IL-2 receptor) (clone 7D4) as described in Proc Natl Acad Sci U S A. 1983 Sep;80(18):5694-8 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD69 (early activation marker) (clone H1.2F3) as described in J Immunol. 1988 Jul 15;141(2):369-76 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal rat antibody specific to mouse Ly-6A/E (Sca-1) (clone D7) as described in J Immunol. 1986 Nov 15;137(10):3240-6 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal rat antibody specific to mouse CD90 (Thy-1) (clone G7) as described in J Exp Med. 1984 Mar 1;159(3):716-30 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD51 (vitronectin receptor, alpha chain) (clone H9.2B8) as described in J Exp Med. 1989 Jun 1;169(6):2173-90 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.